Scientific and Technical Aerospace Reports Volume 39 April 6, 2001
Scientific and Technical Aerospace Reports Volume 39 April 6, 2001
Scientific and Technical Aerospace Reports Volume 39 April 6, 2001
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
the processing for enhancement of selected features <strong>and</strong> fusion of the resultant images are accomplished within a single wavelet<br />
transform framework, the method is computationally efficient <strong>and</strong> flexible enough for incorporation of different enhancement<br />
algorithms <strong>and</strong> their independent optimization. In order to evaluate the performance of the developed technique, we used quantitative<br />
criteria for comparison with histogram equalization <strong>and</strong> unsharp masking. Our method outperformed the two enhancement<br />
approaches during tests on simulated phantoms embedded in noise <strong>and</strong> on mammographic feature phantoms blended into mammograms.<br />
In addition, no spurious artifacts were observed as a result of our redundant wavelet transform based contrast enhancement<br />
scheme.<br />
DTIC<br />
Histograms; Image Processing; Mammary Gl<strong>and</strong>s<br />
<strong>2001</strong>0025737 Naval Research Lab., Washington, DC USA<br />
In Vivo, Fiberoptic-Coupled Radiation Dose Verification System for Prostate Radiotherapy Annual Report, 30 Sep.<br />
1998-29 Sep. 1999<br />
Justus, Brian; Oct. 1999; 12p; In English<br />
Contract(s)/Grant(s): MIPR-8MBLERM8936<br />
Report No.(s): AD-A385826; No Copyright; Avail: CASI; A03, Hardcopy; A01, Microfiche<br />
A fiberoptic-coupled radiation dose verification system for prostate radiotherapy has been built <strong>and</strong> tested under clinical conditions<br />
using solid water phantoms. The dimensions of the radiation sensitive portion of the fiberoptic probe are 1-mm by 0.4-mm<br />
in diameter, providing unsurpassed spatial resolution for radiotherapy applications. The flexible fiberoptic probe is compatible<br />
with use in a medical catheter to provide in vivo monitoring capabilities. The use of fiberoptic bundles to replace discrete optical<br />
elements has resulted in a cost-savings of several thous<strong>and</strong>s of dollars while increasing the reliability of the system. The system<br />
has very good sensitivity for all doses <strong>and</strong> dose - rates encountered in typical external beam radiotherapy procedures. The system<br />
exhibits exceptional linearity <strong>and</strong> has a reproducibility of better than 2% over a wide range of accumulated doses.<br />
DTIC<br />
Cancer; Radiation Therapy; Prostate Gl<strong>and</strong><br />
<strong>2001</strong>0025738 Utah Univ., Salt Lake City, UT USA<br />
Prevalence <strong>and</strong> Characterization of BRCA2 in Male Breast Cancer Cases Annual Report, 15 Jun. 1999-15 Jun. 00<br />
Neuhausen, Susan L.; Jul. 2000; 78p; In English<br />
Contract(s)/Grant(s): DAMD17-96-1-6266<br />
Report No.(s): AD-A385833; No Copyright; Avail: CASI; A05, Hardcopy; A01, Microfiche<br />
Male breast cancer is rare, with an incidence rate of 0.5-1/100,000 per year. The objective of this grant is to study male breast<br />
cancer cases to estimate the attributable risk of male breast cancer due to BRCA2 mutations. 170 CauCASIan male breast cancer<br />
cases are participating, with age at diagnosis ranging from 28-93 years. of the 166 cases with family history data, 49% have a<br />
family history of breast cancer in at least one first- or second- degree relative. Screening for BRCA2 mutations has been completed<br />
for 123 cases. Eleven deleterious mutations were identified in 17 cases, including 6 cases with the common 6174delT mutation.<br />
Based on mutations known to be deleterious, the prevalence of BRCA2 in male breast cancer is 13.8% (17/123) for both population-<br />
<strong>and</strong> clinic-based samples. When only considering population-based samples, the prevalence is 8.5% (8/94). Accounting for<br />
the sensitivity of SSCA of approximately 80%, the prevalence of BRCA2 is 10.6% (8/94)10.80 for population-based samples only<br />
<strong>and</strong> 17.2% for all screened samples. Family history is not a good predictor of BRCA2 mutation status. BRCA2 mutations appear<br />
to be more prevalent in unselected male cases than in unselected female breast cancer cases.<br />
DTIC<br />
Males; Cancer; Diagnosis<br />
<strong>2001</strong>00257<strong>39</strong> Burnham Inst., La Jolla, CA USA<br />
Mechanism of Retinoid Response in Human Breast Cancer Final Report, 26 Sep. 1994-25 Sep. 1999<br />
Xiao-kun, Zhang; Oct. 1999; 71p; In English<br />
Contract(s)/Grant(s): DAMD17-94-J-4440<br />
Report No.(s): AD-A385837; No Copyright; Avail: CASI; A04, Hardcopy; A01, Microfiche<br />
We have investigated the anti-cancer effects of retinoids, the natural <strong>and</strong> synthetic vitamin A derivatives, in breast cancer<br />
cells. Our data demonstrate that retinoids can effectively inhibit growth of breast cancer cells. The growth inhibitory effect of<br />
retinoids is mediated by their induction of retinoic acid receptor beta (RAR-beta) expression, expression, in addition to their suppression<br />
of mitogenic effect of estrogen receptor <strong>and</strong> inhibition of AP-1 activity. Expression of RAR-beta inhibits growth of breast<br />
cancer cells by promoting their apoptosis. Our study also show that retinoid activity in breast cancer cells is regulated by BAG-1,<br />
227
Change language